AKTX · Akari Therapeutics Plc · Exempt Offerings
$8.24
+0.24 (+3.00%)
At close · Oct 30
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based on our recurring losses from operations incurred since inception, our expectation of continuing operating losses for the foreseeable future, negative operating cash flows for the foreseeable future, and the need to raise additional capital to finance its future operations, we have concluded that there is substantial doubt regarding our ability to continue as a going concern within one year after the date that our condensed consolidated financial statements, included in this Form 10-Q (such condensed consolidated financial statements, the "consolidated financial statements") are issued.”View the 10-Q filed Aug 13, 2026
Market Cap
$18.83M
Shares
2.29M
Volume · Oct 30
45.8K
Avg daily vol (3M)
62.13K
Private capital raises reported to the SEC on Form D under Regulation D, showing the offering size, amount sold, minimum investment and number of investors. Public operating companies rarely raise capital this way, so this page is often empty.
| Filed | Type | Industry | Offering | Sold | Exemptions |
|---|---|---|---|---|---|
| 2026-06-03 | New | Other Health Care | $5,500,000 | $1,833,333 | 06b |
| 2025-10-24 | New | Other Health Care | $6,250,000 | $6,250,000 | 06b |
| 2024-01-09 | New | Other Health Care | $2,000,001 | $2,000,001 | 06b |
| 2023-10-19 | New | Other Health Care | $1,971,001 | $1,971,001 | 06c |
| 2022-09-27 | New | Biotechnology | $12,835,000 | $12,835,000 | 06b |
| 2021-07-22 | New | Biotechnology | $12,318,688 | $12,318,688 | 06b |
| 2020-03-11 | New | Biotechnology | $9,554,528 | $9,554,528 | 06b |
Showing 1–7 of 7 filings